Correct Answer: D. Alzheimer’s disease
Down syndrome (Trisomy 21) is strongly associated with early-onset Alzheimer's disease (EOAD), with nearly 100% of Down syndrome patients developing Alzheimer pathology by age 40 if they survive that long. The discriminating factor is the APP gene (amyloid precursor protein) located on chromosome 21. In trisomy 21, there is gene dosage imbalance—three copies of the APP gene instead of two—leading to overproduction of amyloid-beta (Aβ), accelerated amyloid plaque formation, and tau tangles. Neuropathologically, Down syndrome brains show Alzheimer-type changes (amyloid plaques, neurofibrillary tangles) by the third decade of life, decades earlier than sporadic Alzheimer's disease. Clinically, Down syndrome individuals who reach middle age frequently develop dementia, behavioral decline, and cognitive regression. This is a well-established genetic link recognized in all major textbooks and forms the basis for studying Alzheimer's pathogenesis in Down syndrome models. The triplication of chromosome 21 genes, particularly APP, is the mechanistic bridge between Down syndrome and Alzheimer's disease.
Why the other options are wrong
A. Huntington's Disease — Huntington's disease is an autosomal dominant disorder caused by CAG trinucleotide repeat expansion on chromosome 4 (HTT gene), completely unrelated to chromosome 21. While both are neurodegenerative, there is no established genetic or pathophysiological link between Down syndrome and Huntington's disease. This is a distractor exploiting knowledge of neurodegenerative diseases. B. Parkinson Disease — Parkinson's disease involves dopaminergic neuronal loss in the substantia nigra and is primarily associated with alpha-synuclein pathology, not amyloid-beta. Although some Down syndrome patients may develop parkinsonian features as part of advanced neurodegeneration, Parkinson's disease itself has no specific genetic link to trisomy 21. This option confuses general neurodegeneration with specific genetic associations. C. Schizophrenia — Schizophrenia is a psychiatric disorder with complex multifactorial inheritance and dopaminergic/glutamatergic dysfunction. While Down syndrome individuals may have increased psychiatric comorbidities, schizophrenia is not a characteristic or mechanistically linked feature of trisomy 21. This is a trap option mixing psychiatric conditions with genetic syndromes.
High-Yield Facts
- APP gene (chromosome 21) is tripled in Down syndrome, causing amyloid-beta overproduction and early-onset Alzheimer pathology by age 30–40.
- Neuropathological hallmarks (amyloid plaques, neurofibrillary tangles) appear in Down syndrome brains decades earlier than sporadic Alzheimer's disease.
- Nearly 100% of Down syndrome patients develop Alzheimer-type brain changes if they survive to middle age, making it the most common dementia in this population.
- Gene dosage imbalance from trisomy 21 (three copies instead of two) is the mechanistic basis for accelerated amyloid pathology.
- Down syndrome serves as a natural model for studying Alzheimer's disease pathogenesis in research settings.
Mnemonics
APP on 21 → Alzheimer in Down Amyloid Precursor Protein is on chromosome 21. Three copies (trisomy) = three times the amyloid → Alzheimer's. Use this when linking chromosome number to disease. Down 21 + Dementia = Alzheimer Down syndrome (trisomy 21) + cognitive decline in middle age = Alzheimer's disease. This is the only neurodegenerative disease with a direct genetic link to trisomy 21.
NBE Trap
NBE pairs Down syndrome with neurodegenerative diseases to test whether students know the specific genetic mechanism (APP gene dosage) rather than just recognizing "Down syndrome + neurodegeneration." Students unfamiliar with the APP–chromosome 21 link may incorrectly choose Parkinson's or Huntington's based on general neurodegeneration knowledge.
Clinical Pearl
In Indian clinical practice, Down syndrome individuals who survive into adulthood (increasingly common with improved healthcare access) present with progressive dementia, behavioral regression, and loss of self-care skills by the 4th–5th decade—a pattern that should immediately raise suspicion for Alzheimer's disease rather than other neurodegenerative conditions. Screening for cognitive decline in adult Down syndrome patients is now part of standard care protocols.
_Reference: Robbins & Cotran Pathologic Basis of Disease, Ch. 5 (Genetic Disorders); Harrison's Principles of Internal Medicine, Ch. 452 (Alzheimer's Disease and Other Dementias)_